Donor leukocyte infusion for treatment of graft rejection post partially mismatched related donor bone marrow transplant

• Published in: Bone marrow transplantation (Basingstoke) Vol. 22; no. 1; pp. 111 - 113
• Main Authors: GODDER, K. T, ABHYANKAR, S. H, LAMB, L. S, BEST, R. G, GEIER, S. S, PATI, A. R, GEE, A. P, HENSLEE-DOWNEY, P. J
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 01-07-1998
• Subjects: Adult; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Biological and medical sciences; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis; Graft Rejection - therapy; Histocompatibility; Humans; Leukemia, Myeloid, Accelerated Phase - therapy; Leukocyte Transfusion; Male; Medical sciences; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Transplantation, Homologous; Chromosomal aberration; Blood product; HLA-System; Transfusion; Leukocyte; Major histocompatibility system; Male; Myeloproliferative syndrome; Partial; Chronic myelocytic leukemia; Genetics; Adult; Chromosome translocation; Human; Related donor; Malignant hemopathy; Philadelphia chromosome; Case study; Rejection; Chronic; Treatment; Cytogenetics; Abnormal chromosome; Chimerism; Histocompatibility
• ISSN: 0268-3369; 1476-5365
• DOI: 10.1038/sj.bmt.1701278

Graft rejection following bone marrow transplantation is more common in patients who receive their grafts from alternative donors and whose marrow is T cell depleted. Rejection in these patients is mediated by persistent host cells that interfere with successful establishment of donor-derived hematopoietic recovery. We describe a patient with chronic myelogenous leukemia in accelerated phase who rejected a T cell-depleted bone marrow graft, 2 months following partially mismatched related donor bone marrow transplant. Unmanipulated peripheral blood donor leukocyte infusion, without additional chemotherapy or immunosuppressive therapy resulted in complete hematopoietic recovery. Cytogenetics and RFLP demonstrated hematopoietic donor chimerism. The patient did not develop graft-versus-host disease.